Detalhe da pesquisa
1.
MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma.
Br J Haematol
; 162(3): 336-47, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23725219
2.
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Br J Haematol
; 163(5): 581-9, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24117042
3.
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study.
Cancers (Basel)
; 15(5)2023 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900296
4.
A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma.
Blood
; 116(8): e12-7, 2010 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-20479282
5.
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
Haematologica
; 96(10): 1470-7, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21685470
6.
A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples.
Clin Cancer Res
; 15(4): 1367-75, 2009 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19228737
7.
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
J Hematol Oncol
; 13(1): 133, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33032660
8.
Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
Leuk Lymphoma
; 58(4): 859-865, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27499002
9.
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.
PLoS One
; 12(7): e0181366, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28704552
10.
Further psychometric validation of the GAH scale: Responsiveness and effect size.
J Geriatr Oncol
; 8(3): 211-215, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28017687
11.
Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group.
J Clin Oncol
; 22(9): 1664-73, 2004 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15117989
12.
Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.
PLoS One
; 9(6): e101063, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24971577
13.
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.
Leuk Lymphoma
; 53(5): 812-9, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22185637
14.
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
Leuk Res
; 35(4): 431-7, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21030078
15.
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Leuk Lymphoma
; 52(3): 409-16, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21275633
16.
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
Expert Rev Hematol
; 4(1): 9-16, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21322774
17.
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
Leuk Lymphoma
; 50(8): 1283-9, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19557622